CD40 Signaling and Breast Cancer Treatment Response
Author Information
Author(s): Francisco J Esteva, Jing Wang, Feng Lin, Jaime A Mejia, Kai Yan, Kadri Altundag, Vicente Valero, Aman U Buzdar, Gabriel N Hortobagyi, W Fraser Symmans, Lajos Pusztai
Primary Institution: The University of Texas M. D. Anderson Cancer Center
Hypothesis
Can CD40 signaling predict the response to preoperative trastuzumab and chemotherapy in HER-2-overexpressing breast cancer?
Conclusion
CD40 signaling may play a role in determining response to trastuzumab-plus-T/FEC therapy in patients with HER-2-overexpressing breast cancer.
Supporting Evidence
- 64% of patients achieved a pathologic complete response (pCR) after treatment.
- Lower expression of CD40 signaling genes was linked to a higher risk of residual cancer.
- Clinical variables like age and tumor size did not correlate with pCR.
Takeaway
This study found that patients with lower CD40 signaling were more likely to have leftover cancer after treatment, suggesting that CD40 could help predict who will respond to therapy.
Methodology
Gene expression analysis was performed on fine-needle aspiration specimens from 45 patients to identify predictors of response to treatment.
Potential Biases
Potential bias due to the small number of patients with residual disease.
Limitations
The small sample size may limit the ability to identify robust gene expression differences.
Participant Demographics
{"age":{"under_50":19,"over_50":26},"HER-2_status":{"IHC_3+":26,"FISH_positive":42},"estrogen_receptor_positive":{"yes":17,"no":28},"progesterone_receptor_positive":{"yes":10,"no":35},"nuclear_grade":{"intermediate":14,"high":31},"tumor_size":{"T1":5,"T2":24,"T3":8,"T4":8},"nodal_status":{"N0":19,"N1-N3":26}}
Statistical Information
P-Value
p<0.01
Confidence Interval
95% CI, 32% to 76%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website